Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy
OBJECTIVE: The aim of this study is to evaluate the outcomes of gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due to breast cancer. STUDY DESIGN: This was a retrospective cohort study including the patients who were under tamoxifen tr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Network
2022-12-01
|
| Series: | Gynecology Obstetrics & Reproductive Medicine |
| Subjects: | |
| Online Access: | https://gorm.com.tr/index.php/GORM/article/view/1320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857388741984256 |
|---|---|
| author | Şafak Yılmaz Baran Gulsen Dogan Durdag Songul Alemdaroglu Sirin Aydin Husnu Celik |
| author_facet | Şafak Yılmaz Baran Gulsen Dogan Durdag Songul Alemdaroglu Sirin Aydin Husnu Celik |
| author_sort | Şafak Yılmaz Baran |
| collection | DOAJ |
| description |
OBJECTIVE: The aim of this study is to evaluate the outcomes of gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due to breast cancer.
STUDY DESIGN: This was a retrospective cohort study including the patients who were under tamoxifen treatment due to stage I-III breast cancer and who were administered leuprolide acetate for ovarian cysts with low malignancy risk between 2012-2020.
RESULTS: Leuprolide acetate was administered to a total of 16 patients with ovarian cysts. The median age was 39.5 (33-52), the median size of the ovarian cyst was 42.5 (39-79) mm, and the median duration of tamoxifen use was 22 (7-36) months. Leuprolide acetate was administered at doses of 3.75 mg for 1 month at 10 (62.5%) patients, 7.5 mg in two months at 3 (18.75%) patients, and 11.25 mg in three months at 3 (18.75%) patients. Ovarian cysts were regressed after treatment at 13 patients, while 3 patients underwent surgery.
CONCLUSION: Leuprolide acetate can be used as an option in the treatment of ovarian cysts that develop in breast cancer patients under tamoxifen therapy.
Keywords: Breast neoplasms, Gonadotropin-releasing hormone, Ovary, Ovarian cyst, Tamoxifen
|
| format | Article |
| id | doaj-art-ef24f1ee11f64572964676eb2b1cb8df |
| institution | Kabale University |
| issn | 1300-4751 2602-4918 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Medical Network |
| record_format | Article |
| series | Gynecology Obstetrics & Reproductive Medicine |
| spelling | doaj-art-ef24f1ee11f64572964676eb2b1cb8df2025-02-11T21:16:13ZengMedical NetworkGynecology Obstetrics & Reproductive Medicine1300-47512602-49182022-12-0128310.21613/GORM.2022.1320Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen TherapyŞafak Yılmaz Baran0Gulsen Dogan Durdag1Songul Alemdaroglu2Sirin Aydin3Husnu Celik41Department of Obstetrics and Gynecology, Acibadem Dr Sinasi Can Kadikoy Healthcare Group, Istanbul, Turkiye baskent universitybaskent universitybaskent universitybaskent university OBJECTIVE: The aim of this study is to evaluate the outcomes of gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due to breast cancer. STUDY DESIGN: This was a retrospective cohort study including the patients who were under tamoxifen treatment due to stage I-III breast cancer and who were administered leuprolide acetate for ovarian cysts with low malignancy risk between 2012-2020. RESULTS: Leuprolide acetate was administered to a total of 16 patients with ovarian cysts. The median age was 39.5 (33-52), the median size of the ovarian cyst was 42.5 (39-79) mm, and the median duration of tamoxifen use was 22 (7-36) months. Leuprolide acetate was administered at doses of 3.75 mg for 1 month at 10 (62.5%) patients, 7.5 mg in two months at 3 (18.75%) patients, and 11.25 mg in three months at 3 (18.75%) patients. Ovarian cysts were regressed after treatment at 13 patients, while 3 patients underwent surgery. CONCLUSION: Leuprolide acetate can be used as an option in the treatment of ovarian cysts that develop in breast cancer patients under tamoxifen therapy. Keywords: Breast neoplasms, Gonadotropin-releasing hormone, Ovary, Ovarian cyst, Tamoxifen https://gorm.com.tr/index.php/GORM/article/view/1320Breast neoplasmsGonadotropin-releasing hormone agonist triggerOvary Ovarian cyst tamoxifen |
| spellingShingle | Şafak Yılmaz Baran Gulsen Dogan Durdag Songul Alemdaroglu Sirin Aydin Husnu Celik Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy Gynecology Obstetrics & Reproductive Medicine Breast neoplasms Gonadotropin-releasing hormone agonist trigger Ovary Ovarian cyst tamoxifen |
| title | Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy |
| title_full | Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy |
| title_fullStr | Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy |
| title_full_unstemmed | Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy |
| title_short | Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy |
| title_sort | leuprolide acetate treatment for ovarian cysts in breast cancer patients under tamoxifen therapy |
| topic | Breast neoplasms Gonadotropin-releasing hormone agonist trigger Ovary Ovarian cyst tamoxifen |
| url | https://gorm.com.tr/index.php/GORM/article/view/1320 |
| work_keys_str_mv | AT safakyılmazbaran leuprolideacetatetreatmentforovariancystsinbreastcancerpatientsundertamoxifentherapy AT gulsendogandurdag leuprolideacetatetreatmentforovariancystsinbreastcancerpatientsundertamoxifentherapy AT songulalemdaroglu leuprolideacetatetreatmentforovariancystsinbreastcancerpatientsundertamoxifentherapy AT sirinaydin leuprolideacetatetreatmentforovariancystsinbreastcancerpatientsundertamoxifentherapy AT husnucelik leuprolideacetatetreatmentforovariancystsinbreastcancerpatientsundertamoxifentherapy |